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Louis-Philippe BouletAbstract
Asthma affects a significant proportion of elderly patients, but unfortunately, it is responsible for a high asthma-
related morbidity and mortality in this population. This may be related not only to the development of a more
severe asthma phenotype compared to younger patients, with more marked airway obstruction and a more
neutrophilic type of airway inflammation, but also to the presence of many co-morbid conditions. Furthermore, in
older patients, asthma is often under-diagnosed, undertreated and poorly managed. Unfortunately, elderly patients
have usually been excluded of clinical trials on asthma and there is an urgent need to perform more research on
the optimal management of asthma in this population.
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Case report
A 72 years old man is seen at the Emergency Department
(ED) for a recent onset of dyspnea, cough and wheezing
following what seems to be an upper airway viral infection.
He had a past medical history of hypertension, benign pros-
tatic hypertrophy and dyslipidemia. He took a diuretic and
a statin. Two years ago, he was seen at the ED for what was
considered a mild exacerbation of Chronic Obstructive
Pulmonary Disease (COPD) and treated with inhaled bron-
chodilators and an antibiotic but had no measurement of
expiratory flows on that occasion. He had stopped this
medication due to fear of side effects. On questionnaire, he
often had exercise intolerance and occasional symptoms of
cough and wheezing at night or if exposed to respiratory
irritants. He had a smoking history of about 8 pack/years.
On arrival, his forced expiratory volume in 1 s (FEV1) was
45 % of predicted value (p.v.), with a FEV1/ forced vital
capacity (FVC) ratio of 55. A few hours after receiving
bronchodilators and oral corticosteroids, his FEV1 had im-
proved to 70 % p.v. On discharge, he was offered a short-
course of prednisone and started on a short-acting inhaled
bronchodilator on demand plus a medium dose of inhaled
corticosteroid. One month later, his FEV1 was 96 % p.v.
This case of asthma in an elderly patient, probably exac-
erbated by a viral respiratory infection illustrates common
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poor patient report of chronic troublesome symptoms,
often attributed to aging. It also shows the need to con-
firm the degree and reversibility of airway obstruction by
objective means to confirm the diagnosis and offer an ap-
propriate treatment. Careful record of symptoms patterns,
smoking history, lung function tests and assessment of
treatment response helps to assess the patient condition
and treatment needs.Asthma is common and troublesome in the elderly
Asthma is a respiratory disease characterized by variable
respiratory symptoms and airway obstruction associated
with airway hyperresponsiveness (AHR) [1, 2]. These fea-
tures are generally attributed to an airway inflammatory
process with progressive bronchial remodelling [3, 4].
The prevalence of asthma in the elderly has been re-
ported to be equal or even higher than in the general asth-
matic population [5, 6]. As an example, the lifetime and
current prevalence of asthma in patients over 65 years old
was 10.6 and 7.0 % according to a study performed in the
United States [7]. However, elderly patients have the highest
asthma-related mortality, estimated at 51.3 million persons
in USA in 2001 [8] (Table 1). Furthermore, they have a
higher morbidity and rate of hospital admission for asthma
than younger patients [6, 8–12]. This has been attributed to
a frequent under- or mis-diagnosis, poor assessment and
under-treatment of asthma in this group, but also related to
many patients-related care gaps in the management of
asthma in this population [6, 12–16]. Mortality rate fromtributed under the terms of the Creative Commons Attribution 4.0 International
by/4.0/), which permits unrestricted use, distribution, and reproduction in any
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Table 1 Some characteristics of asthma in the elderly
Epidemiological Increased morbidity and mortality
Less frequent atopy
Clinical Underdiagnosed and undertreated
Asthma control more difficult to achieve
Reduced perception of symptoms
Difficulties to perform pulmonary function tests
Numerous co-morbidities
Pathophysiology Mixed (more neutrophilic airway inflammation)
More severe airway obstruction
Loss of lung elastic recoil – reduced respiratory
muscles strength- small airways involvement
Systemic inflammation and immunosenescence
Management
problems
Insufficient understanding of the disease
Memory impairment, hearing loss, poor sight
Psycho-socio-economic problems
Therapy Poor adhesion to therapy and follow-up
Poor inhaler technique (arthritis, understanding…)
Polypharmacy and increased risk of interactions
General Poor nutrition, sedentarity, weight gain
Reduced access to care
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(51.3 per million persons) of any other age group. Further-
more, many elderly asthmatic patients consider that their
respiratory symptoms are normal, associated with aging
and they often delay their consultation to a physician or to
the ED, in addition to have many fears and misconceptions
about their treatment [6, 17].
How aging affects asthma pathophysiology
The elderly seems to suffer from a more severe phenotype
of asthma, more resistant to the treatment, and with poorer
outcomes. This remains however to be more adequately
documented, as it can possibly change our approach to
asthma management in this population. In this regard,
aging is associated with a chronic low grade inflammation
called inflamm-ageing [18]. Senescence can promote
inflammatory (or down-regulate anti-inflammatory) cell
genes, leading to a pro-inflammatory status. Since senes-
cent cells have impaired replicative capacity, with time, this
induces premature apoptosis or alters cell function.
Other factors may play a role in making asthma worse
in the elderly. However little is known for example on
the role of hormonal changes, obesity and metabolic
changes. In this regard, although incidence of obesity
and metabolic syndrome was not higher in postmeno-
pausal asthma patients than controls, Aydin et al. found
an impairment of glucose metabolism and altered adipo-
kine levels in asthma patients. How this may affect
asthma remains to be studied [19].
Physiological changes in the aging lung: the “asthma in
the elderly phenotype”
Age-related physiological changes may influence the
asthma phenotype. We previously showed that airwayobstruction was more marked in elderly asthmatics com-
pared with healthy elderly or younger asthmatic subjects
[20]. This may be due to the addition of a progressive
“physiological” airway obstruction to the changes associ-
ated to asthma. The decline in lung function associated
with aging is considered to result from a reduction in com-
pliance and elastic recoil of the lung, in addition to a re-
duction in respiratory muscle strength while closing and
residual volumes (RV) increase [20, 21]. Furthermore, the
possibility of an increased prevalence of airway hyperre-
sponsiveness (AHR) in the elderly asthmatic compared to
younger subjects has been suggested although determi-
nants of such increase in airway response may differ from
younger patients [21, 22].
In the elderly, asthma is more neutrophilic than in
younger asthmatic patients, whatever the severity of
asthma [20, 23]. This may be related to aging itself, to
respiratory infections, corticosteroid intake or other fac-
tors. A change in microbiome can play a role in this
change in airway inflammatory pattern and even con-
tribute to systemic inflammation [24]. Eosinophils are
also found but their function seems reduced [25]. Total
and specific IgE are reduced and atopy is considered less
frequent but it still affects a large proportion of patients
over 65 years old [6, 26, 27].
Furthermore, two main sub-phenotypes have been de-
scribed in regard to asthma in the elderly according to
the onset of symptoms [9]. ‘Early-onset’, starting in child-
hood or early adulthood, and ‘Late-onset’, starting after
40 years old, this last being associated with a faster lung
function decline, less reversible airway obstruction and
more severe asthma. We however need to know more
about these two types of patients in regard to prognosis
and to better guide the treatment [28].
Assessment of asthma
Asthma is under-diagnosed in the aged patient as symp-
toms, are often underreported or misinterpreted, and
asthma is often confounded with other diseases such as
COPD and heart failure [5, 6]. Furthermore, a poor per-
ception of asthma has also been reported in this popula-
tion [29]. Although very old or physically impaired
patients may have difficulties to perform lung function
tests, those are much useful to assess properly their asth-
matic condition. Some elderly patients may have difficul-
ties to perform spirometry due to physical or cognitive
limitations. Furthermore, they often have a certain degree
of “physiological” irreversible airway obstruction and the
results should be interpreted with caution. Indeed, a fixed
FEV1/FVC ratio of less than 0.70 can lead to overdiagnosis
of airway obstruction due to airway disease. The lower
limit of normal values in uncertain in this age group. So,
additional findings such as a significant improvement in
FEV1 after bronchodilator (12 % and at least 200 ml) may
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expiratory flows, a bronchoprovocation test (e.g. metha-
choline) may be ne necessary. Furthermore, even this is
still debated, it has been suggested that airway hyperre-
sponsiveness (AHR) is more common in the elderly but
its determinants may be different [30, 31]. In a review of
studies looking at AHR according to age, Scichilone et al.
suggested that the data supported an increased prevalence
of AHR in the elderly [32]. Furthermore, although it
would be useful to know more about the determinants of
AHR in this population. The most important seems to be
a reduced lung function and a history of smoking, while
atopy is an independent determinant.
Comorbidities
The number of co-morbidities associated with asthma in-
creases with age and some of those conditions, or the
medications required to treat these last, can sometimes
affect asthma control [33]. Gastro-oesophageal reflux,
chronic rhino-sinusitis, obstructive sleep apnoea and heart
conditions are common in the elderly [33, 34]. Obesity is
common as we gain weight with age, making asthma con-
trol more difficult [35]. Asthma drugs, particularly oral
corticosteroids, may also affect concomitant conditions
such as osteoporosis, cataracts and glaucoma.
Not only could elderly asthmatics who smoke or have a
past history of smoking have a change in their asthma
phenotype, being more severe and more neutrophilic, but
they may have developed the asthma-COPD overlap syn-
drome (ACOS) [1, 36]. In a study by Milanese et al., more
than one-third of elderly asthmatic patients, despite re-
ceiving GINA step 3–4 antiasthmatic therapy, had an
Asthma Control Test Score ≤19, a quarter experiencing at
least one severe asthma exacerbation in the previous year
[37]. One third of patients were classified as having ACOS
due to the presence of chronic bronchitis and/or CO lung
diffusion impairment and this group had poor asthma out-
comes. A more recent study by de Marco et al. also
showed that subjects with ACOS had an earlier age of
asthma onset and the highest hospitalisation rate [38].
These observations may explain the global poorer out-
come in elderly but other factors could also play a role.
Treatment of asthma in the elderly
Asthma in the elderly is commonly under-assessed and
treatment is often not in keeping with current guidelines
[12, 39–43]. The elderly patient may have concerns about
the side-effects of the medication, poor inhaler technique
or insufficient inspiratory flows, and asthma management
can be affected by memory impairment or economic diffi-
culties [6, 12]. Insufficient adherence to therapy is also fre-
quently reported and the above-mentioned problems, in
addition to poor access to care, cultural specificities, or
other personal characteristics may explain such reducedadherence [40, 41]. It is also possible that the elderly asth-
matic is more resistant to therapy either due to a change
in asthma inflammatory phenotype or airway functional
changes. This remains to be further studied.
As elderly patients were usually excluded from random-
ized clinical trials on new treatments, there are few data
on the optimal management of asthma in this population.
It is therefore recommended to use the same guidelines as
for the general population, hoping that further research
will guide future recommendations [1, 6]. Control of
symptoms, optimisation of pulmonary function, and pre-
vention of future risks including exacerbations, while
avoiding side-effects of the medication will guide our ap-
proach, which should be carefully individualized.Nonpharmacological treatment
This type of interventions include smoking cessation, influ-
enza and pneumococcal vaccines. Furthermore, environ-
mental control, promotion of active healthy lifestyle, with
good dietary habits, and regular exercise should be pro-
moted. Weight loss, in the presence of obesity, may mark-
edly improve asthma but is often difficult to achieve [39].
Education of the patient and detection of management
difficulties are mandatory [44, 45]. It has been demon-
strated that with a more aggressive treatment and regular
medical review, acute health care use could be reduced
and quality of life improved in the elderly asthmatic pa-
tient [46]. A multidisciplinary approach has been proposed
for this population, taking into account the various aspects
of pharmacotherapy, education, psycho-socio-economical
problems co-morbid conditions and acute care needs.Pharmacotherapy
As mentioned previously, the approach will be similar to
the general population. Beta-blockers, mainly nonselec-
tive forms, are commonly used in elderly patients and
may result in worsening asthma symptoms. Even topical
forms for treatment of glaucoma have been implicated
in severe bronchoconstriction [47].
Rapid-acting β2-agonists should be provided as rescue
therapy, on demand, at the minimal dose and frequency.
They are usually well tolerated but if they cause tremor
or tachycardia, the dose should be reduced while main-
tenance therapy revised to minimize their need.
As in younger patients, inhaled corticosteroids (ICS) are
the mainstay of asthma treatment in the elderly, although
they are insufficiently used in this population [1, 40]. If in-
sufficient to control asthma, we should first check inhaler
technique, adherence, environmental factors, smoking
status and co-morbid conditions. High-dose ICS and oral
corticosteroids should be avoided whenever possible but if
this is necessary over prolonged time-periods, prevention
of bone loss by appropriate therapy is mandatory.
Key-messages for the clinician
• Asthma in the elderly should be distinguished from other conditions
such as COPD and heart conditions.
• Careful assessment of asthma control and barriers to achievement of
such control - particularly adherence to therapy, poor inhaler techniques,
influence of co-morbidities and other management deficiencies - should
be addressed.
• As we have few data on the optimal management of asthma in this
population, current general guidelines should be used.
• A multi-disciplinary approach should be ensured to look at the various
global aspects of elderly asthmatic health.
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such as formoterol or salmeterol are the first choice of
treatment if a low-dose ICS is insufficient [1]. These treat-
ments are usually well tolerated but side-effects, particu-
larly if the patient is suffering from heart conditions
should be documented. LABA should never be prescribed
as monotherapy in asthma while they often are in COPD
[1, 48]. Furthermore, budesonide/formoterol maintenance
and reliever therapy has been shown to be an effective and
well-tolerated treatment in elderly as in younger asthmatic
patients [49].
Leukotriene receptor antagonists such as montelukast
are safe in the elderly but we have few data on their use-
fulness in this group. Anti-cholinergic agents such as
tiotropium have interesting properties for the elderly pa-
tients as response to this type of agents is well preserved
with age particularly when asthma is severe or in the
presence of side-effects of LABA [50].
Monoclonal antibodies such as omalizumab may be
useful in severely asthmatic atopic patients whatever the
age [51]. Theophylline is now rarely used, but if so, due
to its potential for side-effects and risk of drug interac-
tions, particularly in the aged patient, with frequent
heart conditions and poly-pharmacy, its effects should
be carefully monitored.
As asthma tends to be more severe and is associated
with a high morbidity and increased mortality in the
elderly patient, its treatment should be carefully selected
and its effects checked regularly. As mentioned previ-
ously, as few studies have been performed specifically in
this population, there is an urgent need to evaluate
current and future therapies in this group. Reduced re-
sponse to therapy and resistance to corticosteroids in
the elderly may be another barrier to good control and
adherence to therapy; this may result from a change in
asthma phenotype but it remains to be better docu-
mented (Table 2).
Conclusion
Asthma is common in the elderly and is often confounded
with other conditions such as COPD or cardiac diseases. A
change in asthma phenotype in the elderly and the manyTable 2 Research needed
• What are the effects of aging on lung and immune system
• Better characterize the phenotype
o Role of microbiome and infections
o Role of environment
o Influence of atopy, smoking, co-morbidities, gender
• What are the consequences of recent vs. long-standing asthma
• Determine what is the optimal management of asthma
• How educate the elderly and develop an effective multidisciplinary
approach
• Should drug therapy be better targeted to this population
o How is it different from younger patients?
o What is the response to therapy (short and long-term outcomes)?deficiencies observed in the management of this population
may explain the poor outcomes observed. These care-gaps
should be considered and more research performed on the
optimal management of asthma in the aging patient.Competing interests
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